WCLC 2025 - Posters & ePosters-P3.12.15 Activity and Tolerability of MET Tkis in METex14 NSCLC: Updated Real-World Data From the Italian Biomarker Atlas Database

P3.12.15 Activity and Tolerability of MET Tkis in METex14 NSCLC: Updated Real-World Data From the Italian Biomarker Atlas Database

Back to course

Pdf Summary

This study presents updated real-world data from the Italian ATLAS registry on the clinical activity and safety of MET tyrosine kinase inhibitors (TKIs), specifically capmatinib and tepotinib, in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14). The retrospective multicenter study analyzed outcomes from 185 patients treated across 45 Italian centers between July 2020 and February 2025, with a median follow-up of 18 months. Most patients (83.8%) had an ECOG performance status of 2, 89.7% had received one prior systemic therapy, and 70.3% were treated with MET TKIs.<br /><br />Results demonstrated meaningful clinical benefit from MET TKI therapy. In the overall MET TKI-treated cohort (n=130), median progression-free survival (mPFS) was 8.1 months and median overall survival (mOS) was 13.1 months. Among subgroups, capmatinib (n=78) showed mPFS of 7.5 months and mOS of 14.8 months, while tepotinib (n=52) demonstrated mPFS of 8.7 months and mOS of 11.5 months. Objective response rates were higher in first-line treatment (54.8%) compared to second-line (40.9%).<br /><br />Regarding safety, treatment-related adverse events (TRAEs) were manageable but notable. The most common included peripheral edema, hypoalbuminemia, transaminase increases, interstitial lung disease, asthenia, creatinine rise, and thrombocytopenia. Grade 3 TRAEs were observed with both TKIs, highlighting the need for optimal management of side effects such as edema and pneumonitis to improve patient safety and adherence.<br /><br />In conclusion, this updated real-world evidence confirms that MET TKIs provide meaningful clinical benefit in advanced METex14 mutated NSCLC, particularly in treatment-naïve patients. Further dedicated research into managing adverse events is warranted to maximize therapy safety and effectiveness.

Asset Subtitle

Maria Lucia Reale

Meta Tag

Speaker Maria Lucia Reale

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

MET tyrosine kinase inhibitors

capmatinib

tepotinib

non-small cell lung cancer

MET exon 14 skipping mutation

real-world data

progression-free survival

overall survival

treatment-related adverse events

Italian ATLAS registry